ReviewLife (Basel, Switzerland)2026
In Vivo Prostate Cancer Modelling: From the Pre-Clinical to the Clinical Setting.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Products in Prostate Cancer: Crosstalk Among the Gut Microbiome, Androgen Receptor Signaling, and Epigenetic Regulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer (PCa) remains one of the most prevalent malignancies in men and a leading cause of cancer-related mortality worldwide. Over the last century, PCa modelling has evolved from basic cell-based to more complex systems. Despite this, the clinical translation of research findings is limited by the constraints of current preclinical models. In this review, rat and zebrafish models are highlighted due to their long-standing and emerging translational relevance, respectively. Rat models have played a pivotal role in understanding carcinogenesis and supporting the preclinical evaluation of drugs currently approved for clinical use, such as antiandrogens and androgen-deprivation agents. In parallel, zebrafish models are increasingly recognized as powerful complementary tools for studying tumor biology, metastasis, and drug response, offering unique advantages for high-throughput and personalized medicine approaches. We summarize historical milestones, current advances, and translational perspectives, emphasizing how combining multiple model systems can bridge the gap between molecular research and clinical application. Collectively, the development and refinement of these models represent essential steps toward more predictive and ethically responsible PCa research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.